Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation

Antiviral Therapy

Volumn 8, Issue 1, 2003, Pages 51-56

  Zaccarelli, Mauro ^a   Perno, Carlo Federico ^a   Forbici, Federica ^a   Cingolani, Antonella ^b   Liuzzi, Guiseppina ^a   Bertoli, Ada ^a   Trotta, Maria Paola ^a   Bellocchi, Maria Concetta ^a   Di Giambenedetto, Simona ^b   Tozzi, Valerio ^a   Gori, Caterina ^a   D'Arrigo, Roberta ^a   De Longis, Patrizio ^a   Noto, Pasquale ^a   Girardi, Enrico ^a   De Luca, Andrea ^b   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DATA BASE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE;

EID: 12244282436     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Boucher CA, Cammack N, Schipper P, Schuurman R, Rouse P, Wainberg MA & Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy 1993; 37:2231-2234.
2. Kavlick MF, Shirasaka T, Kojima E, Pluda JM, Hui F Jr, Yarchoan R & Mitsuya H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′deoxy-3′-thiacytidine. Antiviral Research 1995; 28:133-146.
3. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C & Christopherson C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 6:1411-1419.
4. Miller V, Sturmer M, Staszewski S, Groschel B, Hertogs K, de Bethune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD & Larder BA. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.
5. Tisdale M, Alnadaf T & Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrobial Agents & Chemotherapy 1997; 41:1094-1098.
6. Ait-Khaled M, Rakik A, Griffin P, Cutrell A, Fischl MA, Clumeck N, Greenberg SB, Rubio R, Peters BS, Pulido F, Gould J, Pearce G, Spreen W, Tisdale M, Lafon S & CNA3003 International Study Team. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy. Antiviral Therapy 2002; 7:43-51.
7. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G & Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
8. Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C & Tisdale M, on behalf of the CNA3002 International Study Team. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002; 16:1686-1689.
9. Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F & Calvez V. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antiviral Therapy 2001; 6:179-183.
10. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, Keulen W, de Groot T & Boucher CA. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases 1997; 176:398-405.
11. Miller MD, Anton KE, Mulato AS, Lamy PD & Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. Journal of Infectious Diseases 1999; 179:92-100.
12. Miller MD, Margot NA & Lu B. Effect of baseline nucleoside-associated resistance on response to Tenofovir DF (TDF) therapy: integrated analyses of studies 902 and 907. 9th Conference on Retroviruses & Opportunistic Infections; Seattle, Wash., USA, February 24-28, 2002; Abstract 43.
13. Devereux HL, Youle M, Johnson MA & Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999; 13:F123-F127.
14. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antiviral Therapy 2002; 7:11-20.
15. Gomez-Cano M, Rubio A, Puig T, T, Perez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet B & Leal M. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12:1015-1020.
16. Conway B, Montessori V, Rouleau D, Montaner JS, O'Shaughnessy MV, Fransen S, Shillington A, Weislow O & Mayers DL. Primary lamivudine resistance in acute/early human immunodeficiency virus infection. Clinical Infectious Diseases 1999; 28:910-911.
17. Holder DJ, Condra JH, Schleif WA, Chodakewitz J & Emini EA. Virologic failure during combination therapy with Crixivan and RT inhibitors is often associated with expression of resistance-associated mutations in RT only. 6th Conference on Retroviruses & Opportunistic Infections; Chicago, Ill., USA, January 31-February 4, 1999; Abstract 492.
18. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP & Richman DD. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association. 2000; 283:229-234.
19. Larder BA, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
20. Kuritzkes DR, Shugarts D, Bakhtiari M, Poticha D, Johnson J, Rubin M, Gingeras TR, Kennedy M & Eron JJ. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. Journal of Acquired Immune Deficiency Syndromes 2000; 23:26-34.
21. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.
22. Montaner JS, DeMasi R & Hill AM. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998; 12:F23-F28.